Drug Profile

NLS 2

Alternative Names: NLS2

Latest Information Update: 05 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuroLifeSciences
Developer NewcelX
Class Antianaemics; Heavy metals
Mechanism of Action Iron replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Attention-deficit hyperactivity disorder; Restless legs syndrome

Most Recent Events

30 Oct 2025 Kadimastem has merged with NLS Pharmaceutics Ltd to form NewcelX
25 Sep 2020 No development reported - Phase-III for Attention-deficit hyperactivity disorder in France (unspecified route) (NLS Pharmaceutics pipeline, September 2020)
25 Sep 2020 No development reported - Phase-III for Restless legs syndrome in France (unspecified route) (NLS Pharmaceutics pipeline, September 2020)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com